Ito, Moriko

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell

Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research

Cited by 295

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

Ito, M., Barys, L., O'Reilly, T., Young, S., Gorbatcheva, B., Monahan, J., Zumstein-Mecker, S., Choong, P. F., Dickinson, I., Crowe, P., et al. (2011) · Clinical Cancer Research

Cancer-related Molecular PathwaysSarcoma Diagnosis and Treatment

Cited by 115

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 85

The public repository of xenografts enables discovery and randomized phase II-like trials in mice

Townsend, E. C., Murakami, M. A., Christodoulou, A., Christie, A. L., Köster, J., DeSouza, T. A., Morgan, E. A., Kallgren, S. P., Liu, H., Wu, S.-C., et al. (2016) · Cancer Cell

Acute Lymphoblastic Leukemia researchAcute Myeloid Leukemia Research

Cited by 80

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Weisberg, E., Halilovic, E., Cooke, V. G., Nonami, A., Ren, T., Sanda, T., Simkin, I., Yuan, J., Antonakos, B., Barys, L., et al. (2015) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysAcute Myeloid Leukemia Research

Cited by 56